Web Analytics

Anti Phospholipid screen

GWB-521213

1x96 Assays
$261.80
Add to Cart

Description

1. INTRODUCTION
The first study on the anti-phospholipid antibodies began in 1906 when Wasserman introduced a serological test for syphilis. In 1942 it was found the active component that is a phospholipid indicated by the name of Cardiolipin. In the 50's it was observed that a large number of people appeared to be positive for syphilis tests but did not show any evidence of disease. At the beginning the phenomenon was classified as a series of false positive syphilis test, then a more accurate analysis revealed, for this group of patients, a high prevalence of autoimmune disorders including Systemic Lupus Eritematosus (SLE) and Sjögrens syndrome. The term lupus anticoagulant (LA), used for the first time in 1972, derives from experimental observations in which it was observed an increased risk of thrombosis, paradoxically, with the presence of some anticoagulants factors; the term LA is not totally correct, in fact the disease is present more frequently in patients without lupus and it is associated with thrombosis rather than to abnormal bleeding. Some years later the role of a cofactor has been investigated, the β2-glycoprotein I (apolipoprotein H) also said β2GPI, and its interactions with anionic phospholipids in human serum / plasma. This cofactor is a β-globulin with a molecular weight of 50 kDa that has the concentration of 200 g / mL in plasma. The β2GPI is involved in the regulation of blood coagulation, inhibiting the intrinsic way. β2GPI in vivo is associated with negatively charged substances such as anionic phospholipids, heparin and lipoproteins. The region that binds phospholipids is in its fifth domain. The acronym "aPL" (anti-phospholipid antibodies) indicates improperly antibodies directed against phospholipids negatively charged like Cardiolipin (CL), Phosphatidyl serine (PS) Phosphatidyl inositol (PI) and phosphatidic acid (PA); more correctly the term anti-phospholipid antibodies indicate those antibodies directed against the complex between β2GPI and anionic phospholipids that can bind to the fifth domain of β2GPI. Among these, the Cardiolipin is the most commonly used phospholipid as an antigen for determining the aPL with ELISA method. Diagnostic laboratories measure the antibodies directed against the complex between β2GPI and negatively charged phospholipids, as Phosphatidyl serine (PS) Phosphatidyl inositol (PI) and phosphatidic acid (PA). Some researchers suggest the use of PS instead of Cardiolipin in ELISA assays, for a more precise diagnosis. However, these antibodies against phospholipids are less commonly used, even if their use may increase the clinical sensitivity of patients samples with suspected Anti-phospholipid Syndrome (APS), but it can’ t replace the determination of autoantibodies anti-Cardiolipin.

2. INTENDED USE
Anti-phospholipid screen is an indirect solid phase immunoassay kit for the quantitative measurement of IgG and IgM class auto-antibodies directed against β2-glycoprotein mediated anionic phospholipids in human serum or plasma, including Cardiolipin, Phosphatidyl serine, Phosphatidyl inositol, phosphatidic acid on serum or plasma. The assay is intended for research use only as an aid in the diagnosis of increased risk of thrombosis in patients with Systemic Lupus Eritematosus (SLE) or similar disorders. Anti Phospholipid Screen kit is intended for laboratory use only.

3. PRINCIPLE OF THE ASSAY
Anti-phospholipid screen test is based on the binding of present antibodies on human serum directed against the antigenic complex between anionic phospholipids (Cardiolipin, Phosphatidyl Serine, Phosphatidyl Inositol, Phosphatidic acid) and β2-Glycoprotein; these complexes are coated on the microplate. Any present antibody in calibrators, controls or prediluted patient samples bind to its respective antigen. After 60 minutes incubation the microplate is washed with wash buffer for removing non-reactive serum components. An anti-human IgG conjugate solution (Conjugate IgG, reactive 4) or an anti-human IgM conjugate solution (Conjugate IgM, reactive 5) recognize IgG or IgM class antibodies respectively, bound to the immobilized antigens. After a 30 minutes incubation any excess enzyme conjugate, which is not specifically bound is washed away with wash buffer. A chromogenic substrate solution containing TMB is dispensed into the wells. After 15 minutes incubation the color development is stopped by adding the stop solution. The solutions color change into yellow. The amount of color is directly proportional to the concentration of IgG (or IgM) antibodies present in the original sample.

Additional Information

Name Anti Phospholipid screen
Related Product Names Auto-antibodies against phospholipids (aPL) ELISA, aPL ELISA Kit, Anti Cardiolipin (CL), Phosphatidyl serine (PS), Phosphatidyl inositol (PI), and Phosphatidic acid (PA) ELISA Kit Thrombosis Assay
Molecular Weight 0.5
Datasheets / Downloads GWB-521213 Datasheet
Concentration Lot Specific
Applications Enzyme immunoassay for the quantitative determination of auto-antibodies against phospholipids in human serum or plasma
Reactivity Human
Storage Store all the kit reagents at 2-8°C. Do not freeze. Reagents are stable until the expiration date when stored and handled as directed Unused antigen coated microwell strips should be resealed securely in the foil pouch containing desiccants and stored at
Intended Use Research Use Only